10x Genomics $TXG Stock Holdings Boosted by Franklin Resources Inc.

Franklin Resources Inc. increased its position in 10x Genomics (NASDAQ:TXG) by 474.6% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 382,760 shares of the company’s stock after acquiring an additional 316,144 shares during the period. Franklin Resources Inc. owned approximately 0.31% of 10x Genomics worth $4,432,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in 10x Genomics by 235.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company’s stock worth $62,016,000 after purchasing an additional 4,987,195 shares during the last quarter. Millennium Management LLC boosted its position in shares of 10x Genomics by 434.5% during the first quarter. Millennium Management LLC now owns 5,377,492 shares of the company’s stock worth $46,946,000 after buying an additional 4,371,327 shares during the period. Jacobs Levy Equity Management Inc. grew its holdings in 10x Genomics by 3,619.6% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,166,723 shares of the company’s stock worth $10,185,000 after buying an additional 1,135,356 shares in the last quarter. ARK Investment Management LLC increased its position in 10x Genomics by 8.1% in the 2nd quarter. ARK Investment Management LLC now owns 13,892,103 shares of the company’s stock valued at $160,871,000 after acquiring an additional 1,046,390 shares during the period. Finally, Iron Triangle Partners LP bought a new stake in 10x Genomics during the 1st quarter valued at $8,730,000. 84.68% of the stock is currently owned by institutional investors.

10x Genomics Trading Down 3.9%

Shares of NASDAQ TXG opened at $18.08 on Tuesday. 10x Genomics has a twelve month low of $6.78 and a twelve month high of $20.34. The firm has a 50-day moving average of $14.11 and a two-hundred day moving average of $12.78. The company has a market capitalization of $2.29 billion, a price-to-earnings ratio of -29.16 and a beta of 2.13.

10x Genomics (NASDAQ:TXG) last released its earnings results on Thursday, November 6th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.05. 10x Genomics had a negative net margin of 11.89% and a negative return on equity of 11.50%. The business had revenue of $149.00 million for the quarter, compared to the consensus estimate of $142.50 million. During the same period in the previous year, the firm earned ($0.30) EPS. The business’s revenue for the quarter was down 1.7% on a year-over-year basis. 10x Genomics has set its Q4 2025 guidance at EPS. As a group, research analysts predict that 10x Genomics will post -1.43 earnings per share for the current year.

Insider Activity

In other news, CEO Serge Saxonov sold 13,261 shares of the firm’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $19.00, for a total transaction of $251,959.00. Following the completion of the sale, the chief executive officer directly owned 1,021,556 shares of the company’s stock, valued at $19,409,564. This trade represents a 1.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Adam Taich sold 11,888 shares of 10x Genomics stock in a transaction on Monday, November 24th. The stock was sold at an average price of $19.00, for a total value of $225,872.00. Following the completion of the transaction, the chief financial officer owned 297,385 shares in the company, valued at $5,650,315. The trade was a 3.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 33,432 shares of company stock worth $635,208. Insiders own 9.39% of the company’s stock.

Wall Street Analyst Weigh In

TXG has been the subject of several recent analyst reports. Wall Street Zen cut 10x Genomics from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. UBS Group increased their target price on shares of 10x Genomics from $13.00 to $14.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of 10x Genomics in a research note on Monday, November 17th. Morgan Stanley set a $20.00 price target on shares of 10x Genomics in a research note on Monday. Finally, Zacks Research cut shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. Six investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $15.12.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.